UserWiki:LockPicker/Drafts/1cP-LSD - PsychonautWiki

UserWiki:LockPicker/Drafts/1cP-LSD


Yellow-warning-sign1.svg

This page has not been fully approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.

Summary sheet: LockPicker/Drafts/1cP-LSD
LockPicker/Drafts/1cP-LSD
1cP-LSD.svg
Chemical Nomenclature
Common names 1cP-LSD
Substitutive name 1-Cyclopropionyl-d-lysergic acid diethylamide
Systematic name (6aR,9R)-4-cyclopropionyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 15 µg
Light 25 - 75 µg
Common 75 - 150 µg
Strong 150 - 300 µg
Heavy 300 µg +
Duration
Total 8 - 12 hours
Onset 20 - 60 minutes
Come up 45 - 120 minutes
Peak 3 - 5 hours
Offset 3 - 5 hours
After effects 6 - 24 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

1-Cyclopropionyl-d-lysergic acid diethylamide (known as 1cP-LSD) is a novel semisynthetic psychedelic substance of the lysergamide class. It induces its psychedelic effects by acting on serotonin receptors in the brain.[1] 1cP-LSD is closely related to 1P-LSD and LSD. It is reported to produce similar to identical effects.

Little is known about the pharmacology. Incubation of 1CP‐LSD with human serum led to the formation of LSD, indicating that it may act as a prodrug for LSD.[1] Characteristic effects include geometric visual hallucinations, time distortion, enhanced introspection, and ego loss.

1cP-LSD appeared on the online research chemical market as a new legal alternative to LSD when 1P-LSD was prohibited in Germany.

It is highly advised to use harm reduction practices if using this substance.

History and culture

 

This History and culture section is a stub.

As a result, it may contain incomplete or wrong information. You can help by expanding it.

1cP-LSD first appeared on the online research chemical market in July 2019.[2]

Chemistry

 

This chemistry section is incomplete.

You can help by adding to it.

1cP-LSD is a semisynthetic compound of the lysergamide family. It is similar to LSD and is named for the cyclopropionyl group bound to the nitrogen of the polycyclic indole group of LSD. The cyclopropionyl group consists of a carbonyl ring with the chemical formula C3H6 bound to an amino group. The structure of 1cP-LSD contains a polycyclic group featuring a bicyclic hexahydro indole bound to a bicyclic quinoline group. At carbon 8 of the quinoline, an N,N-diethyl carboxamide is bound.

Pharmacology

 

This pharmacology section is incomplete.

You can help by adding to it.

Further information: Serotonergic psychedelic

Based on its structural similarity to LSD, 1cP-LSD likely acts as a partial agonist at the 5-HT2A receptor. The psychedelic effects are thought to primarily come from its efficacy at the 5-HT2A receptors distributed throughout the brain. 1cP-LSD also likely displays binding activity at a wide range of monoamine receptors, such as those for dopamine and norepinephrine. However, there is currently no data to support these claims.

Subjective effects

 
This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
 

Visual effects
 

Cognitive effects
 

Multi-sensory effects
 

Combination effects

  • Alcohol - Alcohol's central depressant effects can be used to reduce some of the anxiety and tension produced by 1cP-LSD. However, alcohol can cause dehydration, nausea and physical fatigue which can negatively impact the direction of the trip. Users are advised to pace themselves and drink a portion of their usual amount.
  • Benzodiazepines - Benzodiazepines are highly effective at reducing the intensity of 1cP-LSD's effects through the general suppression of brain activity.
  • Cannabis - Cannabis strongly intensifies the sensory and cognitive effects of 1cP-LSD. Extreme caution is advised when using this combination as it can significantly increase the chances of a negative psychological reaction like anxiety, confusion and psychosis. Users are advised to start off with only a fraction of their usual cannabis dose and take long breaks between hits to avoid over intake.
  • Dissociatives - 1cP-LSD enhances the cognitive, visual and general hallucinatory effects of dissociatives. Dissociative-induced holes, spaces, and voids and internal hallucinations become more vivid and intense on 1cP-LSD. These effects correspond with an increased risk of confusion, delusions, and psychosis.
  • MDMA - 1cP-LSD and MDMA are highly synergistic and mutually enhance each other's physical, cognitive, and visual effects. The synergy between these substances is unpredictable, and it is advised to start with markedly lower doses than one would take for each individually. There is some evidence that suggests LSD increases the neurotoxicity of MDMA, which may be relevant to 1cP-LSD as well.[3][4][5]

Experience reports

There are currently 0 experience reports which describe the effects of this substance in our experience index.

Additional experience reports can be found here:

Toxicity and harm potential

 

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

The toxicity and long-term health effects of recreational 1cP-LSD use have not been studied. This is because 1cP-LSD is a research chemical with almost no history of human use.

However, as with LSD and psychedelics in general, it is likely that 1cP-LSD can act as a trigger for those with underlying mental disorders. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly when outside of a supervised medical setting.

It is strongly recommended that one uses harm reduction practices when using this substance.

Overdose

1cP-LSD has no known toxic dose. However, higher doses increase the risk of adverse psychological reactions. These reactions include anxiety, delusions and panic attacks. Medical attention is usually not needed except in the case of severe psychotic episodes or the ingestion of fake acid (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the acute negative cognitive effects of 1cP-LSD.

Tolerance and addiction potential

Dangerous interactions

 

This dangerous interactions section is a stub.

As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit. The following substances are listed on the assumption that 1cP-LSD possesses a similar if not the same dangerous interactions profile as LSD, and may include more due to its status as an unstudied research chemical.

Legal status

 

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Germany: 1cP-LSD is not a controlled substance under the BtMG (Narcotics Act)[7] or the NpSG (New Psychoactive Substances Act).[8] It is legal, as long as it is not sold for human consumption, according to §2 AMG.[9]
  • Sweden: Sweden's public health agency suggested classifying 1cP-LSD as a dangerous substance on December 18, 2019.[10]
  • United Kingdom: 1cP-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.[11]

See also

References

  1. 1.0 1.1 Brandt, Simon D.; Kavanagh, Pierce V.; Westphal, Folker; Stratford, Alexander; Odland, Anna U.; Klein, Adam K.; Dowling, Geraldine; Dempster, Nicola M.; Wallach, Jason; Passie, Torsten; Halberstadt, Adam L. (March 16, 2020). "Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1‐cyclopropanoyl‐d‐lysergic acid diethylamide (1CP‐LSD)". Drug Testing and Analysis. 12 (6): 812–826. doi:10.1002/dta.2789. eISSN 1942-7611. ISSN 1942-7603. OCLC 231680670. PMID 32180350. 
  2. "1cP-LSD". Google Trends. Retrieved July 14, 2020. 
  3. Armstrong, B. D., Paik, E., Chhith, S., Lelievre, V., Waschek, J. A., & Howard, S. G. (2004). Potentiation of (DL)‐3, 4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptor partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939. Neuroscience Research Communications, 35(2), 83-95. https://doi.org/10.1002/nrc.20023
  4. Potentiation of MDMA-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists | https://indiana.pure.elsevier.com/en/publications/potentiation-of-34-methylenedioxymethamphetamine-induced-dopamine
  5. Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. | https://www.ncbi.nlm.nih.gov/pubmed/17572501
  6. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  7. "Betäubungsmittelgesetz (BtMG)" [Narcotics Act (BtMG)] (PDF) (in German). Bundesamt für Justiz [Federal Office of Justice]. July 28, 1981. Retrieved July 14, 2020. 
  8. "Neue-psychoaktive-Stoffe-Gesetz (NpSG)" [New Psychoactive Substances Act (NpSG)] (PDF) (in German). Bundesamt für Justiz [Federal Office of Justice]. November 21, 2016. Retrieved July 14, 2020. 
  9. "§2 Arzneimittelgesetz (AMG)" [§2 Pharmaceutical Act (AMG)] (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved July 14, 2020. 
  10. "Tjugotre ämnen föreslås klassas som narkotika eller hälsofarlig vara" [Twenty-three substances are proposed to be classified as drugs or dangerous goods] (in Swedish). Folkhälsomyndigheten [Public Health Agency of Sweden]. December 18, 2019. Retrieved July 14, 2020. 
  11. "Psychoactive Substances Act 2016". legislation.gov.uk. Retrieved July 14, 2020.